OTCMKTS:MJARF

MJardin Group Competitors

$0.06
-0.01 (-14.39 %)
(As of 04/20/2021 05:19 PM ET)
Add
Compare
Today's Range
$0.06
Now: $0.06
$0.07
50-Day Range
$0.07
MA: $0.10
$0.14
52-Week Range
$0.03
Now: $0.06
$0.22
Volume58,239 shs
Average Volume160,882 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

MJardin Group (OTCMKTS:MJARF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying MJARF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to MJardin Group, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

MJardin Group (OTCMKTS:MJARF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.

Valuation & Earnings

This table compares MJardin Group and Abacus Health Products' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MJardin GroupN/AN/AN/AN/AN/A
Abacus Health ProductsN/AN/AN/AN/AN/A

Profitability

This table compares MJardin Group and Abacus Health Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MJardin GroupN/AN/AN/A
Abacus Health ProductsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for MJardin Group and Abacus Health Products, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MJardin Group01002.00
Abacus Health Products0000N/A

MJardin Group currently has a consensus target price of $0.10, indicating a potential upside of 69.78%. Given MJardin Group's higher possible upside, equities analysts clearly believe MJardin Group is more favorable than Abacus Health Products.

Summary

MJardin Group beats Abacus Health Products on 1 of the 1 factors compared between the two stocks.

Acreage (OTCMKTS:ACRGF) and MJardin Group (OTCMKTS:MJARF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares Acreage and MJardin Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcreageN/AN/AN/A
MJardin GroupN/AN/AN/A

Earnings and Valuation

This table compares Acreage and MJardin Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcreageN/AN/AN/AN/AN/A
MJardin GroupN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Acreage and MJardin Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acreage01202.67
MJardin Group01002.00

Acreage presently has a consensus price target of $8.4333, suggesting a potential upside of 204.45%. MJardin Group has a consensus price target of $0.10, suggesting a potential upside of 69.78%. Given Acreage's stronger consensus rating and higher probable upside, equities analysts plainly believe Acreage is more favorable than MJardin Group.

Summary

Acreage beats MJardin Group on 3 of the 3 factors compared between the two stocks.

MJardin Group (OTCMKTS:MJARF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for MJardin Group and Applied Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MJardin Group01002.00
Applied Biosciences0000N/A

MJardin Group presently has a consensus target price of $0.10, suggesting a potential upside of 69.78%. Given MJardin Group's higher probable upside, equities analysts clearly believe MJardin Group is more favorable than Applied Biosciences.

Valuation & Earnings

This table compares MJardin Group and Applied Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MJardin GroupN/AN/AN/AN/AN/A
Applied BiosciencesN/AN/AN/AN/AN/A

Profitability

This table compares MJardin Group and Applied Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MJardin GroupN/AN/AN/A
Applied BiosciencesN/AN/AN/A

Summary

MJardin Group beats Applied Biosciences on 1 of the 1 factors compared between the two stocks.

MJardin Group (OTCMKTS:MJARF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares MJardin Group and Ayr Strategies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MJardin GroupN/AN/AN/A
Ayr StrategiesN/AN/AN/A

Valuation & Earnings

This table compares MJardin Group and Ayr Strategies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MJardin GroupN/AN/AN/AN/AN/A
Ayr StrategiesN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for MJardin Group and Ayr Strategies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MJardin Group01002.00
Ayr Strategies01602.86

MJardin Group presently has a consensus target price of $0.10, indicating a potential upside of 69.78%. Ayr Strategies has a consensus target price of $34.8571, indicating a potential upside of 63.96%. Given MJardin Group's higher possible upside, equities research analysts clearly believe MJardin Group is more favorable than Ayr Strategies.

Summary

Ayr Strategies beats MJardin Group on 2 of the 3 factors compared between the two stocks.

MJardin Group (OTCMKTS:MJARF) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Valuation and Earnings

This table compares MJardin Group and Can B's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MJardin GroupN/AN/AN/AN/AN/A
Can BN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for MJardin Group and Can B, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MJardin Group01002.00
Can B0000N/A

MJardin Group currently has a consensus target price of $0.10, suggesting a potential upside of 69.78%. Given MJardin Group's higher possible upside, equities research analysts plainly believe MJardin Group is more favorable than Can B.

Profitability

This table compares MJardin Group and Can B's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MJardin GroupN/AN/AN/A
Can BN/AN/AN/A

Summary

MJardin Group beats Can B on 1 of the 1 factors compared between the two stocks.

Cansortium (OTCMKTS:CNTMF) and MJardin Group (OTCMKTS:MJARF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Cansortium and MJardin Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cansortium00103.00
MJardin Group01002.00

Cansortium currently has a consensus price target of $1.20, suggesting a potential upside of 11.11%. MJardin Group has a consensus price target of $0.10, suggesting a potential upside of 69.78%. Given MJardin Group's higher probable upside, analysts clearly believe MJardin Group is more favorable than Cansortium.

Earnings and Valuation

This table compares Cansortium and MJardin Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CansortiumN/AN/AN/AN/AN/A
MJardin GroupN/AN/AN/AN/AN/A

Profitability

This table compares Cansortium and MJardin Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CansortiumN/AN/AN/A
MJardin GroupN/AN/AN/A

Summary

Cansortium beats MJardin Group on 2 of the 3 factors compared between the two stocks.


MJardin Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84-5.4%$0.00N/A0.00News Coverage
Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77-0.0%$0.00N/A0.00
Applied Biosciences logo
APPB
Applied Biosciences
0.5$0.21-81.0%$0.00N/A0.00Increase in Short Interest
Gap Down
AYRSF
Ayr Strategies
1.4$21.26-0.0%$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.52-3.5%$0.00N/A0.00Gap Up
Cansortium logo
CNTMF
Cansortium
0.9$1.13-4.5%$0.00N/A0.00Gap Down
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$3.90-2.8%$0.00N/A0.00
Choom logo
CHOOF
Choom
0.5$0.09-2.3%$0.00N/A0.00Gap Up
CPHRF
Cipher Pharmaceuticals
1.2$1.07-0.9%$0.00N/A0.00
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.20-15.0%$0.00N/A0.00News Coverage
Gap Up
Cosmos logo
COSM
Cosmos
0.5$6.30-8.7%$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Down
Cresco Labs logo
CRLBF
Cresco Labs
1.3$11.25-6.5%$0.00N/A0.00
Curaleaf logo
CURLF
Curaleaf
1.6$12.77-2.5%$0.00N/A0.00
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00-33.3%$0.00N/A0.00Gap Up
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.15-1.7%$0.00N/A0.00
EVIO logo
EVIO
EVIO
0.6$0.00-8.7%$0.00N/A0.00
Flower One logo
FLOOF
Flower One
0.4$0.19-13.5%$0.00N/A0.00High Trading Volume
Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05-0.0%$0.00N/A0.00Gap Down
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01-11.3%$0.00N/A0.00Gap Up
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$26.82-1.2%$0.00N/A0.00
GTEC logo
GGTTF
GTEC
0.6$0.57-6.3%$0.00N/A0.00
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.85-0.7%$0.00N/A0.00
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01-11.8%$0.00N/A0.00
Hexo logo
HYYDF
Hexo
0.6N/AN/A$0.00N/A0.00
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$65.83-5.2%$0.00N/A0.00
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.18-6.7%$0.00N/A0.00Gap Up
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.27-2.4%$0.00N/A0.00Gap Up
KNHBF
ICC International Cannabis
0.6N/AN/A$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04-0.0%$0.00N/A0.00Gap Up
Isodiol International logo
ISOLF
Isodiol International
0.4$0.06-0.2%$0.00N/A0.00
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.38-10.2%$0.00N/A0.00Gap Down
KHTRF
Knight Therapeutics
1.2$4.15-0.7%$0.00N/A0.00
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01-1.4%$0.00N/A0.00
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.05-1.0%$0.00N/A0.00News Coverage
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.37-1.4%$0.00N/A0.00Increase in Short Interest
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.26-7.7%$0.00N/A0.00Gap Up
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$35.05-1.3%$0.00N/A0.00Increase in Short Interest
MYHI
Mountain High Acquisitions
0.5$0.02-17.0%$0.00N/A0.00Gap Up
PHCEF
Pharmacielo
0.7$1.34-6.7%$0.00N/A0.00Gap Up
Plus Products logo
PLPRF
Plus Products
1.1$0.51-2.0%$0.00N/A0.00Gap Down
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00-4.0%$0.00N/A0.00
PCYN
Procyon
0.4$0.60-0.0%$0.00N/A0.00
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01-2.8%$0.00N/A0.00Gap Up
SANP
Santo Mining
0.5$0.00-16.3%$0.00N/A0.00Gap Down
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$12.76-2.1%$0.00N/A0.00Increase in Short Interest
News Coverage
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40-0.0%$0.00N/A0.00News Coverage
TerrAscend logo
TRSSF
TerrAscend
1.7$9.95-1.9%$0.00N/A0.00
The Flowr logo
FLWPF
The Flowr
1.5$0.22-2.5%$0.00N/A0.00Gap Up
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.2$0.28-8.1%$0.00N/A0.00Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.